September 21, 2020 -- City of Hope has licensed intellectual property for its chlorotoxin chimeric antigen receptor (CLTX-CAR) T-cell therapy to Chimeric Therapeutics.
Chimeric, an Australian biotechnology company, has acquired the exclusive worldwide rights to develop and commercialize certain patents related to City of Hope's CLTX-CAR T cells, as well as further develop the therapy for other cancers.
Uniquely, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and is engineered to serve as the CAR recognition domain. The CLTX CAR T-cell therapy was developed and tested by City of Hope researchers. In early studies, the team found that CLTX-CAR T cells recognized and killed broad populations of glioblastoma cells while ignoring nontumor cells in the brain and other organs. The therapy is currently being evaluated in a phase I clinical trial to treat glioblastoma.